Hypocalcemiccrisis developed in a patient with monophasicsynovial sarcoma after amputation of the right leg, followed by long-term treatment with cisplatin and doxorubicin. Laboratory data revealed severe hypomagnesemia and hypocalcemia. High normal intact parathyroid hormone (PTH), elevated mid-region PTHand undetectable osteocalcin levels had already been found before the appearance of obvious symptomsconcomitantly associated with moderate hypomagnesemia and hypocalcemia. Further, both PTHlevels measured by two different methods gradually decreased until the initiation of magnesium supplementation. The magnesiumsupplement immediately relieved the tetany, and induced striking increases in both intact and mid-region PTHlevels transiently and continuous elevations of osteocalcin levels. These results suggest that magnesiumdepletion has dual effects on PTHsecretion, from stimulation to inhibition, as hypomagnesemiaprogresses. Both relative hypoparathyroidism and refractoriness of bone to PTH were thought to be responsible for hypocalcemia due to hypomagnesemia.
Introduction

Cisplatin
(cis-diamminedichloroplatinum)-induced tiypomagnesemia and hypocalcemia have been reported in several patients (1) (2) (3) , and the renal magnesium wasting due to its nephrotoxic effect is suggested to be pathogenic (4) . Doxorubicin hydrochloride is also thought to possess a similar Lowering effect on serum magnesium (3, 5, 6) , although its sole effect has not been fully evaluated. Regarding the mechanisms involved in the development of hypocalcemia in magnesium deficiency, several conflicting data have been reported in various conditions (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Here we report a case of hypomagnesemiaand hypocalcemia due to cisplatin and doxorubicin treatment for monophasic synovial sarcoma, and evaluate the detailed changes in parathyroid function and bone turnover using sensitive assays of parathyroid hormone (PTH) and bone Crla protein [(BGP) osteocalcin].
Case Report A 15-year-old boy was admitted to our hospital in 1990 for the evaluation of a tumor, measuring 1 1x10x5 cm, in his right leg and was diagnosed to have a monophasic fibrous synovial sarcoma. He was preoperatively treated with an intraarterial infusion of20 mgofcisplatin three times a week and 100 mgof doxorubicin hydrochloride monthly for 4 months. Total doses of cisplatin and doxorubicin were 1,110 mg and 380 mg, respectively. From the day after the operation (above-knee amputation of the right leg) on Dec. 17, he manifested symptoms of tetany and paresthesia on his fingers and lips. There were positive Trousseau's sign as well as Chvostek's sign and hyperactive deep tendon reflexes. Investigation on Dec. 18 revealed low serum calcium corrected with serum albumin (20) (cCa) of 5.6 mg/dl (normal, 8.3-10.3) , high serum inorganic phosphate (Pi) of 5.8 mg/dl (normal, 2.0-4.4), low serum magnesium (Mg) of 0.4 mEq/L (normal, 1.3-1.9) and low serum potassium (K) of 3.0 mEq/L (normal, 3.4-4.8) . Acidbase balance showed metabolic alkalosis. Complete blood count showed pancytopenia due to chemotherapy which had continued from October. Creatinine clearance was 79.3 ml/ min. The patient was given a total of 1,700 mg of calcium gluconate per day until Dec. 22. As the intravenous administration of calcium gluconate did not relieve the symptomseffectively, an infusion of 2,000 mgof magnesiumsulfate per day was started in the evening of Dec. 22. Laboratory data just before the magnesiumsupplementation showed cCa of 6.2 mg/ PTHin Hypomagnesemiadue to Cisplatin dl, Pi of 6.6 mg/dl, plasma ionized calcium of 0.760 mM (normal, 1.067-1.283), Mg of 0.4 mEq/L and creatinine phosphokinase of 5, 042 IU/L (normal, . Serum PTH levels were 0.6 ng/ml with c-terminal assay (normal, <0.5), 540 pg/ml with mid-portion assay normal, both int-PTH and mid-PTH decreased in spite of progressive hypomagnesemia and hypocalcemia, and increased strikingly soon after magnesiumsupplementation. This increase in PTH after magnesiumsupplementation was transient. Although serum cCa and Mgwere almost restored to normal levels during the course of the magnesiumsupplementation, int-PTH and mid-PTHwere restored to values within the normal range 5 days and 14 days later, respectively. BGP, which was normal under hypomagnesemia, increased after magnesium supplementation. The patient is now well.
Discussion
Long-term treatment with cisplatin and doxorubicin for malignant synovial sarcoma seemed to be very effective in the prevention of metastasis. Both cisplatin (1) (2) (3) (4) and doxorubicin (3, 5, 6) have already been shown to cause hypomagnesemia due to magnesiumleaking from the kidney.
Regarding the cause of hypocalcemia secondary to hypomagnesemia, several possible mechanisms have been suggested (7): diminished end organ responsiveness to PTH (8) (9) (10) , decreased release of calcium from bone (19), or relative hypoparathyroidism (5, 6, 1 1-18) . In these reports, the measurement of PTH in hypomagnesemia caused by combined chemotherapy containing doxorubicin revealed mostly low values (5, 6) . In the present patient, the values of mid-region PTH (44-68) (21) and intact PTH, a recently developed sensitive assay of intact molecules ofPTH (1-84) (22), did not show low levels. The mid-region and intact PTHwere elevated and high normal, respectively, under asymptomatic mild hypomagnesemiaon Dec. 1 1, and tended to decrease, followed by progressive hypomagnesemiauntil the initiation of magnesium supplementation. Previous reports (14) (15) (16) 25) revealed that serum PTHlevels during hypomagnesemia due to chronic alcoholism or malabsorption were not always low. Allgrove et al (16) showed that amino-terminal PTH values were elevated under mild or moderate hypomagnesemia and becamelower or undetectable as magnesiumdepletion became more profound. Our present result was consistent with this finding. The level of serummagnesium showinga changefroma suppressive effect to a stimulative effect on intact PTHsecretion wasestimated to lie at about 0.4 mEq/L (0.2 mmol/L) or more in our patient, which was almost equal to the level described in the previous in vivo report (16) or in vitro report (26). These findings suggest that previously reported variances in serum immunoreactive PTHlevels are due to differences in the degree (and duration to some extent) of hypomagnesemiaand hypocalcemia. Magnesium supplementation induced a striking increase in mid-region PTHand intact PTHin the present patient as in the previous reports (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] in which serum values ofPTHwere measured with traditional assays. This increase indicates that the stimulating drive for PTHsecretion in response to severe hypocalcemia was suppressed by magnesium depletion. Interestingly, there were somedissociations between serum mid-region and intact PTHlevels. Mid-region and intact PTH were high and within the normal range, respectively, in the symptomatic condition, and the mid-region PTHtook more time to normalize compared with the intact PTHafter magnesium supplementation. Regarding the dissociation during the latter period, the difference in restoration time from the transient increase between mid-region and intact PTHmight be due to a difference in degradation time, because it has been shown that the half-life (rate of disappearance from the circulation) of intact PTHwas 5-10 min in normal humans (27) and 21 min in patients after parathyroid adenomectomy(28), while that of mid-region PTH was 1-2 hours (27). However, the dissociation in the pretreatment period cannot be explained solely by the difference in degradation time. A recent report on a hypomagnesemicpatient whose condition was due to chronic alcoholism (29) as reported in patients with fractures (3 1 ). The further increase in serum BGPlevels after the magnesiumsupplementation and the preoperative low BGPlevel implied that magnesium depletion attenuated the bone turnover. These findings suggest that a refractoriness of target organs to PTHcontributes to the hypocalcemia due to hypomagnesemiaas an additional mechanism (7-10, 14, 29) . In the present patient, mild hypomagnesemia and hypocalcemiawere already present without obvious symptoms prior to amputation, and apparent symptomsof hypocalcemia appeared only after amputation surgery. The stress of amputation, alterations in the electrolyte balance by intravenous fluids during the operation, and/or progressive metabolic alkalosis were considered to trigger the apparent symptoms of hypomagnesemiaand hypocalcemia. The restoration of serum calciumafter magnesium supplementationseemedto occur earlier than that of magnesiumin our young patient, in contrast to the previous reports which described the later normalization of serum calcium (9-1 1, 14, 16, 17) . Our patient's amputation surgery might have accelerated bone remodeling, which was suggested by the postoperative increase of BGP, resulting in sufficient mobilization of calcium from bone. The postoperative immobilization status (32) of the patient might also have contributed to the earlier restoration of serum calcium.
In summary, the present report describes the development and restoration of functional hypoparathyroidism caused by hypomagnesemiadue to cisplatin and doxorubicin. Our findings suggest that magnesiumdepletion affects PTHsecretion in a biphasic fashion: from stimulation to inhibition as hypomagnesemia progresses. It is also suggested that magnesium depletion causes the refractoriness of bone to PTH,which is partly responsible for the hypocalcemia.
